Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis

Next Previous
Trial Profile

A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olopatadine (Primary) ; Loratadine
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use

Most Recent Events

  • 27 Feb 2023 Primary endpoint has been met. (Ocular itching 7(1) minutes post-CAC at Visit 3), as per presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 27 Feb 2023 Primary endpoint has been met. (Ocular itching 7(1) minutes post-CAC at Visit 4b), as per presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 27 Feb 2023 Primary endpoint has been met. (Ocular itching 5(1) minutes post-CAC at Visit 4b), as per presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top